Accessibility setting

Search

Select language

Skip to secondary menu

Skip to content

Jehovah’s Witnesses

English

Beta Thalassemia (Adults)

Beta Thalassemia Major—Pharmacological Induction of Fetal Hemoglobin Synthesis

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia.

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Source‎: Iran J Blood Cancer 2009;1(4):147-50.

Indexed‎: IMEMR 107228

http://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en

Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy.

Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D.

Source‎: Eur J Haematol 1996;56(5):326-8.

Indexed‎: PubMed 8641410

http://www.ncbi.nlm.nih.gov/pubmed/8641410

Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease.

Fucharoen S, Siritanaratkul N, Winichagoon P, Chowthaworn J, Siriboon W, Muangsup W, Chaicharoen S, Poolsup N, Chindavijak B, Pootrakul P, Piankijagum A, Schechter AN, Rodgers GP.

Source‎: Blood 1996;87(3):887-92.

Indexed‎: PubMed 8562958

http://www.ncbi.nlm.nih.gov/pubmed/8562958

Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports.

Karimi M, Cohan N, Pishdad P.

Source‎: Hematology. 2015;20(1):53-7.

Indexed‎: PubMed 24717020

DOI‎: 10.1179/1607845414Y.0000000168

http://www.ncbi.nlm.nih.gov/pubmed/24717020

Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?

Banan M.

Source‎: Ann Hematol 2013;92(3):289-99.

Indexed‎: PubMed 23318979

DOI‎: 10.1007/s00277-012-1671-3

http://www.ncbi.nlm.nih.gov/pubmed/23318979

Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.

Musallam KM, Taher AT, Cappellini MD, Sankaran VG.

Source‎: Blood 2013;121(12):2199-212.

Indexed‎: PubMed 23315167

DOI‎: 10.1182/blood-2012-10-408021

http://www.ncbi.nlm.nih.gov/pubmed/23315167

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Source‎: Int J Hematol 2012;95(1):51-6.

Indexed‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

http://www.ncbi.nlm.nih.gov/pubmed/22180324

Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia.

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Source‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Indexed‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

http://www.ncbi.nlm.nih.gov/pubmed/21602718

Fetal globin gene inducers: novel agents and new potential.

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Source‎: Ann N Y Acad Sci 2010;1202:158-64.

Indexed‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

http://www.ncbi.nlm.nih.gov/pubmed/20712788

Hydroxyurea therapy in 49 patients with major beta-thalassemia.

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Source‎: Arch Iran Med 2009;12(3):295-7.

Indexed‎: PubMed 19400608

http://www.ncbi.nlm.nih.gov/pubmed/19400608

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Source‎: Transfusion 2007;47(10):1830-6.

Indexed‎: PubMed 17880608

http://www.ncbi.nlm.nih.gov/pubmed/17880608

Fetal globin induction--can it cure beta thalassemia?

Perrine SP.

Source‎: Hematology Am Soc Hematol Educ Program 2005:38-44.

Indexed‎: PubMed 16304357

http://www.ncbi.nlm.nih.gov/pubmed/16304357

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Source‎: Haematologica 2004;89(10):1172-8.

Indexed‎: PubMed 15477200

http://www.ncbi.nlm.nih.gov/pubmed/15477200

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules.

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Source‎: Acta Haematol 2004;111(4):189-95.

Indexed‎: PubMed 15153710

http://www.ncbi.nlm.nih.gov/pubmed/15153710


The medical section of jw.org is designed as an informational resource primarily for use by clinicians and other health-care professionals. It provides neither medical advice nor treatment recommendations and does not substitute for an appropriately qualified health-care provider. The clinical literature cited is not published by Jehovah’s Witnesses, but it outlines transfusion-alternative strategies that might be considered. It is the responsibility of each qualified health-care provider to maintain awareness of new information, discuss options for care, and assist patients in making choices in accord with their medical condition, wishes, values, and beliefs. Not all listed strategies are appropriate or acceptable to all patients.

Patients: Always seek the advice of your doctor or other qualified health-care provider regarding medical conditions or treatments. Check with a doctor if you suspect you are ill.

The use of this website is governed by its terms of use.